Microbio Co Ltd (4128) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Microbio Co Ltd (4128) has a cash flow conversion efficiency ratio of -0.010x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-100.20 Million ≈ $-3.16 Million USD) by net assets (NT$10.20 Billion ≈ $321.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 4128 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Microbio Co Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Microbio Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Microbio Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Microbio Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ganesha Ecosphere Limited
NSE:GANECOS
|
0.074x |
|
Te Chang Construction Co Ltd
TWO:5511
|
0.048x |
|
Chien Kuo Construction Co Ltd
TW:5515
|
0.378x |
|
Bera Holding AS
IS:BERA
|
0.013x |
|
PT Estee Gold Feet Tbk
JK:EURO
|
-0.067x |
|
Bhansali Engineering Polymers Limited
NSE:BEPL
|
0.036x |
|
Akebia Ther
NASDAQ:AKBA
|
0.955x |
|
Highlight Tech
TWO:6208
|
0.085x |
Annual Cash Flow Conversion Efficiency for Microbio Co Ltd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Microbio Co Ltd from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see 4128 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$10.20 Billion ≈ $321.50 Million |
NT$85.27 Million ≈ $2.69 Million |
0.008x | -81.28% |
| 2024-12-31 | NT$11.87 Billion ≈ $373.94 Million |
NT$529.90 Million ≈ $16.69 Million |
0.045x | +871.28% |
| 2023-12-31 | NT$13.50 Billion ≈ $425.34 Million |
NT$-78.15 Million ≈ $-2.46 Million |
-0.006x | -157.28% |
| 2022-12-31 | NT$14.01 Billion ≈ $441.34 Million |
NT$141.57 Million ≈ $4.46 Million |
0.010x | +159.17% |
| 2021-12-31 | NT$13.84 Billion ≈ $436.15 Million |
NT$53.98 Million ≈ $1.70 Million |
0.004x | -54.37% |
| 2020-12-31 | NT$12.85 Billion ≈ $404.91 Million |
NT$109.82 Million ≈ $3.46 Million |
0.009x | +6.78% |
| 2019-12-31 | NT$9.04 Billion ≈ $284.89 Million |
NT$72.36 Million ≈ $2.28 Million |
0.008x | +388.65% |
| 2018-12-31 | NT$9.68 Billion ≈ $304.91 Million |
NT$15.85 Million ≈ $499.33K |
0.002x | +238.29% |
| 2017-12-31 | NT$8.30 Billion ≈ $261.53 Million |
NT$-9.83 Million ≈ $-309.70K |
-0.001x | +94.47% |
| 2016-12-31 | NT$8.41 Billion ≈ $265.04 Million |
NT$-180.25 Million ≈ $-5.68 Million |
-0.021x | -18.36% |
| 2015-12-31 | NT$8.94 Billion ≈ $281.77 Million |
NT$-161.90 Million ≈ $-5.10 Million |
-0.018x | +1.39% |
| 2014-12-31 | NT$9.10 Billion ≈ $286.68 Million |
NT$-167.04 Million ≈ $-5.26 Million |
-0.018x | +9.53% |
| 2013-12-31 | NT$8.70 Billion ≈ $274.25 Million |
NT$-176.63 Million ≈ $-5.56 Million |
-0.020x | +3.13% |
| 2012-12-31 | NT$6.32 Billion ≈ $199.08 Million |
NT$-132.36 Million ≈ $-4.17 Million |
-0.021x | +51.99% |
| 2011-12-31 | NT$6.23 Billion ≈ $196.39 Million |
NT$-271.95 Million ≈ $-8.57 Million |
-0.044x | -142.24% |
| 2010-12-31 | NT$5.04 Billion ≈ $158.75 Million |
NT$520.41 Million ≈ $16.40 Million |
0.103x | +211.97% |
| 2009-12-31 | NT$5.26 Billion ≈ $165.69 Million |
NT$-485.10 Million ≈ $-15.28 Million |
-0.092x | -15.56% |
| 2008-12-31 | NT$1.79 Billion ≈ $56.53 Million |
NT$-143.21 Million ≈ $-4.51 Million |
-0.080x | -8.41% |
| 2007-12-31 | NT$1.29 Billion ≈ $40.78 Million |
NT$-95.30 Million ≈ $-3.00 Million |
-0.074x | -1038.56% |
| 2006-12-31 | NT$559.40 Million ≈ $17.62 Million |
NT$4.39 Million ≈ $138.25K |
0.008x | -- |
About Microbio Co Ltd
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia in women before menopause and relieved dysmenorrhea. It also involved in the trading of organic foods; sale of beverages; pr… Read more